Rollout of a coronavirus vaccine offers chance to demonstrate distribution system’s value to policymakers, and Davis knows that could impact the trajectory of issues such as track and trace that will return to prominence after the pandemic eases.
Many believe COVID-19 offers the pharmaceutical industry a chance to bolster its public reputation by creating a vaccine that would end the pandemic. A PR makeover always seemed more a hope than a possibility given the low esteem in which people tend to hold drug companies, as well as the general fracturing of American society.
But vaccines are moving forward nonetheless, and with any luck in a few months they could begin to be available...
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
A total of 748 key medicines are now affected by the four-month stock requirement, compared with 422 in 2021.
The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.
